Major Genetic Determinants of Extended-Spectrum $\beta$-Lactamase (ESBL), Carbapenemase, Fosfomycin and Colistin Resistance in *Escherichia Coli* from Intensive Care Units

Ahmed Mhawesh1*, Marwa khudair2 and Omer N. Abbas3

Abstract: *Escherichia coli* (E. coli) strains placed in predominant nosocomial bacteria in intensive care units (ICUs), resulting in severe drug-resistant infections. Non-susceptibility to $\beta$-lactams and last-line drugs such as Fosfomycin and Colistin cause limited availability of infections eradication. The objective of this study included the determination of genes encoding extended-spectrum $\beta$-lactamase (ESBL), Carbapenemase, Colistin, and Fosfomycin resistance in clinical isolates of *E. coli* in ICUs. A total of 200 *E. coli* isolates were identified from ICU settings. The CTX-M-1, SHV, IMP and OXA-48 genes were detected for $\beta$-lactamases using the polymerase chain reaction (PCR) technique. The fosA3 and mcr-1 and mcr-2 genes were also detected for resistance against Fosfomycin and Colistin. The CTX-M1, SHV, IMP and OXA-48 genes were detected in 60 (30%), 56 (28%), 28 (14%) and 4 (2%) of isolates. none of the *E. coli* isolates had the mcr-2 and fosA3 genes. Despite the existence of resistance genes to the third-generation antibiotics and Carbapenemase s, any isolates had genes for resistance to Fosfomycin and Colistin. More studies are needed to follow the resistance genes against last-resort antibiotics.

Key words: *Escherichia coli*, beta-lactamase, Fosfomycin, Colistin, ESBLs.

Introduction

*Escherichia coli* (E. coli) organism is known as the cause of wound and urinary infections, pneumonia, meningitis, sepsis, etc., so it is unique along with other members of the normal intestinal flora1-9. This bacterium is facultatively anaerobic, oxidase-negative and catalase-positive. *E. coli* is one of the most common microorganisms in the normal intestinal flora of humans and warm-blooded animals6-9. It colonizes in the host intestine a few days after birth. Today, the increasing spread of ESBLs in hospitals is a significant barrier to properly treating infectious diseases. Among them, those that produce ESBLs restricted treatment of menacing infections. *E. coli* is a common species in the production of ESBL enzymes and is a major cause of nosocomial infections8,14. On the other hand, resistance to carbapenems is a severe issue that is caused by various enzymes. Intensive care units are basic settings where the resistant strains spread. Major ESBL and Carbapenemase genes include CTX-M, SHV, TEM, IMP, VIM and OXA-48, which are spread with various resistance levels5,12,13,14. The aim of our study included detection of genes encoding ESBLs (SHV and CTX-M1), Carbapenemase s (OXA-48 and IMP1), Colistin and Fosfomycin among *E. coli* from ICU settings.

Materials and methods

Bacterial isolates and patients

450 stool samples were initially collected and cultured onto the blood agar and MacConky media (MERk, Germany). Suspected colonies were subjected to the IMVIC test to identify them. These tests included indole production, motility in the SIM medium, vogue pro square and citrate consumption. 200 *E. coli* was determined using biochemical tests from ICU settings. Patients included 84 males and 112 females with an age mean of 52.21 years. All the patients had more than 24h of hospitalization.

Citation: Mhawesh A, khudair M, Abbas ON. Major Genetic Determinants of Extended-Spectrum $\beta$-Lactamase (ESBL), Carbapenemase, Fosfomycin and Colistin Resistance in *Escherichia Coli* from Intensive Care Units. Revis Bionatura 2022;7(1). 11. http://dx.doi.org/10.21931/RB/2022.07.01.11

Received: 20 June 2021 / Accepted: 10 November 2021 / Published: 15 February 2022

Publisher’s Note: Bionatura stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Phenotypic detection of ESBLs

The production of ESBLs enzymes was confirmed using the synergy and combine tests. The synergy test included a culture of isolate onto the Mueller Hinton agar and placing two disks co-amoxiclav and ceftazidime near each other. Additionally, the combined disk included placement of ceftazidime disk and a blank disk that contained clavulanic acid. Any increase in the inhibition zone exhibited the production of ESBLs.

DNA isolation

The total genomic DNA was extracted using the boiling method. After preparation of bacterial suspension from a single colony of isolates in DDH2O, each tube was boiled for 10min and centrifuged at 10,000rpm for 5min. The supernatant was used as a DNA template. The quantification of the DNA load was evaluated using the 260/280 ratio and Nanodrop device to be >1.8.

Detection of ESBLs and Carbapenemase genes

The ESBL and Carbapenemase genes, including CTX-M, SHV, IMP and OXA-48 were detected using PCR and using specific primers shown in table 1. The PCR conditions included 94°C for 3min, and a 30 cycle of 94°C, annealing for 45s, 72°C for 1min and final extension of 72°C for 10min. The master mix (6µL), template DNA (1µL), each F and R primer (1µL) and DDH2O (5µL) were mixed in the reaction tube.

Detection of mcr-1, mcr-2 and fosA3 genes

The PCR assay was employed for the amplification of Fosfomycin (fosA3) and Colistin (mcr-1, mcr-2) resistant genes using specific primer sequences and annealing shown in table 2.19.

The thermal cycle for detecting mcr-1 and mcr-2 genes was similar to that of previous, but the annealing temperature included 56°C and 58°C. The PCR products were run onto the 1% gel agarose in 1X Tris Borate EDTA (TBE) and visualized using safe dye.

Data analysis

The prevalence of genes was analyzed by SPSS version 20, and the un-paired T-test and ANOVA options were used for assessment of significance defining <0.05 cut-off value.

Results

Patients and isolates

Of 200 patients, 84 males and 112 females with a mean

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequence 5’----3’</th>
<th>Annealing T</th>
<th>Amplicon size (bp)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>blaSHV</td>
<td>F: GCGGGTTATTTGTCGC</td>
<td>56</td>
<td>1016</td>
<td>16,17</td>
</tr>
<tr>
<td></td>
<td>R: ATGCCGCGCCAGTCA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BlaIMP</td>
<td>F: GGGTTGGGCGGTGTCCTA</td>
<td>62</td>
<td>198</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R: TCTATTCCGGCTGTGTC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>blactXM</td>
<td>F: CGCTTTGCGATGTCGAC</td>
<td>59</td>
<td>500</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>R: ACCCGGATATCGTTGTC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>blaoXA-48</td>
<td>F: CGCCCGCGTCAAGATAGGACAC</td>
<td>65</td>
<td>484</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>R: TCGGCCAGCGCGATAGGACAC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Table 1.* Specific primers for detection of CTX-M, SHV, IMP and OXA-48 genes.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence: 5’ to 3’</th>
<th>Product size (bp)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>fosA3</td>
<td>F: GGCAATTTATCGACG</td>
<td>350</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>R: AGACCATCCCCCTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mcr-1</td>
<td>F: AGTCGGTTTGTCGTCG</td>
<td>320</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>R: AGATCTGTTGGTCGGCTT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mcr-2</td>
<td>F: CAAGGGTTGCGAGGCAGTTT</td>
<td>715</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>R: TCGCCGCGGAGAAGCATAC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Table 2.* The primer sequences for the detection of Fosfomycin and Colistin resistance genes.
The age of 52.21 years were included. The previous hospitalization was determined in 177 of them (p<0.001). All the patients had more than 24h of hospitalization. Moreover, 189 (p<0.0001) of them had previous beta-lactam administration. The age range of patients and rate of ESBLs production has been depicted in table 3. 70 patients were infected with ESBL-producing E. coli.

As shown in table 3, the age range 51-60 years were significantly more infected with ESBL-producing E. coli, but other age groups were not significantly associated with the ESBL production.

<table>
<thead>
<tr>
<th>Age range (years)</th>
<th>ESBL (%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10</td>
<td>0</td>
<td>Non-S</td>
</tr>
<tr>
<td>11-20</td>
<td>0</td>
<td>Non-S</td>
</tr>
<tr>
<td>21-30</td>
<td>5</td>
<td>Non-S</td>
</tr>
<tr>
<td>31-40</td>
<td>18</td>
<td>Non-S</td>
</tr>
<tr>
<td>41-50</td>
<td>20</td>
<td>Non-S</td>
</tr>
<tr>
<td>51-60</td>
<td>50</td>
<td>0.031, S</td>
</tr>
<tr>
<td>61-70</td>
<td>7</td>
<td>Non-S</td>
</tr>
<tr>
<td>&gt;70</td>
<td>0</td>
<td>Non-S</td>
</tr>
</tbody>
</table>

Table 3. The age range of patients and ESBL production.

DESBLS and Carbapenemase genes

The CTX-M1, SHV, IMP and OXA-48 genes were detected in 60 (30%), 56 (28%), 28 (14%) and 4 (8%) of isolates (figures 1-4).

Notably, three isolates had all the CTX-M1, SHV, IMP, and OXA-48 genes. The patients had ages>60 years and had previous hospitalization and antibiotic consumption.

The association of ESBL genes with previous hospitalization and antibiotic prescription has been depicted in table 4. As shown, there was a significant relationship between the previous hospitalization and antibiotic prescription and the rate of ESBL production (p<0.0001).

PCR detection of mcr-1, mcr-2 and fosA3 genes

None of the E. coli isolates had the mcr-1, mcr-2 and fosA3 genes.

Discussion

Despite the fact that infectious diseases and their treatment have always been considered throughout human history, their changes and mutations have caused failure in their eradication [1,6,11]. On the other hand, even this has caused new strains, and their prevalence has increased the range of these diseases in new forms. Microbial strains which produce enzymes hydrolyzing broad-spectrum antimicrobials are a concern. Gram-negative species are one of the significant barriers to the definitive treatment of infectious diseases [20-22]. E. coli is a common species in the production of ESBL enzymes and is the main cause of nosocomial infections, especially urinary tract infections and sepsis, visceria, liver abscesses, cholangitis and cholecystitis and pancreatic abscesses. Therefore, due to the growing number of these strains in nosocomial infections and ICU centers, determining the pattern of E. coli resistance genes encoding ESBLs and Carbapenemase enzymes in clinical samples was one of the objectives of this study.

In this study, the rate of CTX-M SHV ESBLs included 30% (n=60) and 28% (n=56), respectively. The production of ESBL enzymes is encoded by several genetic factors that produce over 340 different types of beta-lactamase enzymes. These enzymes are classified into different classes based on their genetic identification and similarity. There are different reports of the prevalence of these enzymes in the Enterobacteriaceae family in the world. Studies in other parts of the world have reported a different prevalence. It seems that the emergence and spread of ESBL-bearing bacteria are often due to the widespread use of beta-lactam drugs so that today we see an increasing number of these bacteria in various parts of hospitals such as ICUs. In a study by Tasi et al. in Turkey, the production of ESBL in E. coli strains was equal to 17% [23], and in the study of Villegas in Colombia, it was reported 3.4% [24].

On the other hand, the Zhou study in Shanghai showed that 47.4% of E. coli isolated from patients produced these enzymes [25]. In another study by Wu et al. in Taiwanese hospitals, ESBL-producing E. coli was 18.18% as one of the most abundant ESBL-producing isolates [25]. In Lebanon, the rate was 28.1%. This rate is much lower in Japan, less than 0.1% in E. coli and 0.3% in Klebsiella spp. Elsewhere in Asia, it has been reported from 4.8% to 28% [25,26]. Comparison of these results shows that the rate of ESBL in isolated strains from different countries and in one country from one hospital to another va-
ries depending on the infection control system and patient’s treatment method in each hospital. Various risk factors are involved in increasing the number of ESBL-producing bacteria, such as long-term hospital stay, overuse of antibiotics (including third-generation cephalosporins), use of vascular and urinary catheters, and prolonged ICU storage history of surgery and irrational and inadequate use of antimicrobial treatments. This study also observed that prior hospitalization and antibiotic use are significant risk factors.

We also observed that the IMP and OXA-48 genes were detected in 28 (14%) and 4 (8%) isolates, respectively. Fortunately, none of the isolates had genes encoding Fosfomycin (fosA3) and Colistin (mcr-1 and mcr-2) resistance.

Conclusions

In this study, a high rate of E. coli isolates from ICU were ESBL-producing by amplifying CTX-M and SHV genes. Fortunately, none of the isolates had genes encoding Fosfomycin (fosA3) and Colistin (mcr-1 and mcr-2) resistance. More studies are needed to follow the resistance genes against last-resort antibiotics.

Table 4. The association of ESBL genes with previous hospitalization and antibiotic prescription.

<table>
<thead>
<tr>
<th>ESBL genes</th>
<th>Previous hospitalization</th>
<th>Prior antibiotic use</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTX-M1</td>
<td>58/60 (96.7%)</td>
<td>51/60 (85%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>SHV</td>
<td>54/56 (96.4%)</td>
<td>49/56 (7.5%)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Figure 3. PCR gel electrophoresis of IMP with 198 bp size.

Figure 4. PCR gel electrophoresis of OXA-48 gene with 484 bp size.

Informed Consent Statement

Not applicable.

Data Availability Statement

The results of this study will be found under the rules of the journal and related link.

Acknowledgments

To my colleagues working in laboratories inside my college and to those who helped me collect samples and resources.

Conflict of interest

None to declare.

Bibliographic references

8. Owaif HAHA. Regulation of Transcription of the Escherichia coli Group 2 Capsule Gene Clusters: The University of Manchester (United Kingdom); 2017.
Major Genetic Determinants of Extended-Spectrum β-Lactamase (ESBL), Carbapenemase, Fosfomycin and Colistin Resistance in Escherichia Coli from Intensive Care Units


